Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis

Table 1 Demographic and clinical characteristics of patients at baseline

Characteristics	Levels	n (%)
Age (year)	≤ 60	76 (51.4)
	> 60	72 (48.6)
Gender	Male	91 (61.5)
	Female	57 (38.5)
ECOG score	0-1	136 (91.9)
	2	12 (8.1)
Location	Right colon	50 (33.8)
	Left colon and rectum	98 (66.2)
Surgery	No	27 (18.4)
	Yes	120 (81.6)
No. of metastases	1	89 (60.1)
	≥ 2	59 (39.9)
Liver metastasis	No	64 (43.2)
	Yes	84 (56.8)
Lung metastasis	No	106 (71.6)
	Yes	42 (28.4)
RAS	Wild type	22 (14.9)
	KRAS mutation	26 (17.6)
	NRAS mutation	2 (1.4)
	Unknown	98 (66.2)
Group	SOC	108 (73.0)
	Chemoimmunotherapy	40 (27.0)

ECOG: Eastern Cooperative Oncology Group; SOC: Standard-of-care.